Pharma Branding Agency: Product Names, Corporate Identity and the FDA Rules Behind Them

Updated October 2026 · Written and maintained by the Progression Agency strategy team

Pharma branding is the work of naming and identifying a medicine, and the company behind it, so that prescribers, pharmacists, patients and partners recognize it, remember it and never mistake it for another product, all inside the FDA rules that govern proprietary names, labeling and promotion. A pharma branding agency builds the corporate brand, product names and identities, the architecture that ties a portfolio together, packaging systems and launch assets, and it works beside the regulatory, medical and legal reviewers who sign them off. This page is written for brand leads, marketing directors and founders at pharmaceutical and biotech companies. Progression Agency is based in New York City and works with clients across the United States and worldwide.

What is pharma branding?

It is branding where the name is also a safety device. A pharmaceutical brand has to persuade and differentiate like any other, but its name, its packaging and its promotional assets are regulated as labeling, so every creative choice is also a compliance choice.

FDA’s guidance on proprietary names starts from that point: health care professionals use the name to prescribe, transcribe, dispense and administer a product, and an end user who cannot tell one name from another may hand a patient the wrong medicine. The same guidance cites a 1999 Institute of Medicine estimate of 7,000 deaths a year in the United States from medication errors, which is why a drug name is screened for look-alike and sound-alike risk before anyone asks whether it is memorable. A consumer brand can be clever. A drug brand has to be clever and impossible to confuse.

Why a drug name is treated as part of the product

Under the Federal Food, Drug, and Cosmetic Act a drug is misbranded if its labeling is false or misleading in any particular, and the proprietary name appears on that labeling: the prescribing information, the container label, the carton and the promotional pieces. FDA therefore reviews the name as part of the application, gives a tentative decision early and grants final acceptance only when the product itself is approved. A rejected name late in a program means new packaging artwork, new launch materials and a new trademark filing, which is the most expensive way to learn the rules.

Where branding stops and pharma marketing begins

A working pharma marketing definition covers everything that moves a product toward prescribers and patients: channels, campaigns, medical education, field enablement, patient support and measurement. Branding is the narrower layer underneath it, the name, the identity, the voice and the rules for using them. Our pharmaceutical marketing agency page covers the channels and the medical, legal and regulatory review stages in detail, so this page does not repeat them.

Product branding vs corporate branding in pharma

A corporate brand is built for the people who fund, partner with and work for the company; a product brand is built for the people who prescribe, dispense and take the medicine. They share a visual language at most, because the audiences and the rules differ.

The corporate brand: the story behind the pipeline

The company brand carries the scientific thesis, the pipeline, the leadership and the culture. It appears in investor decks, on partnering pages, at conferences, in recruiting and in the press. It can be expressive in a way a product brand rarely can, but it inherits one hard limit from the product side: it may not present an investigational medicine as safe or effective.

Product brands: two names that always travel together

Every product brand pairs a proprietary name, the coined word the company owns, with an established name, the nonproprietary name the public owns. The pairing is not a design preference. The regulations decide how close together the two names sit, how large the established name must be and how often it appears, so the logo is designed around those constraints from the first sketch.

Biotech branding before approval

A clinical-stage company often needs a strong corporate identity years before it has a product to name. Under 21 CFR 312.7, a sponsor may not represent in a promotional context that an investigational new drug is safe or effective for the use under investigation, although the full exchange of scientific information stays open. Biotech branding at that stage therefore leans on the science, the people and the platform, and keeps program code names out of anything that reads as a product launch.

Brand architecture across a portfolio

Portfolio decisions carry safety consequences. FDA advises against introducing a new product under an existing product’s name when the active ingredient differs, against reusing the name of a discontinued product, and against building every product name on the sponsor’s own name, because a row of names such as ABCName1 and ABCName2 sits alphabetically on a pharmacy shelf. Where two products share an ingredient but differ sharply in use, FDA will consider two distinct names, case by case.

How does FDA review a proposed drug brand name?

FDA evaluates the proposed proprietary name for medication-error risk and for promotional or misbranding concerns, gives a tentative acceptance or non-acceptance within set review goals, and confirms the name only when it approves the product.

The method is set out in two guidance documents worth reading in full before a naming project starts: Best Practices in Developing Proprietary Names for Human Prescription Drug Products (final, December 2020) and Contents of a Complete Submission for the Evaluation of Proprietary Names (April 2016). The first was prepared by FDA’s Division of Medication Error Prevention and Analysis together with the Office of Prescription Drug Promotion and the promotional labeling branch at the biologics center, which tells you whose concerns a name has to survive.

When will FDA look at a proposed name?

FDA does not evaluate proposed proprietary names until a product has completed phase 2 trials. The request goes in as a separate submission, to the pending application or, before one exists, to the active IND. A submission can carry two names, a primary and an alternate; the alternate is reviewed only if the primary is found unacceptable and the sponsor confirms in writing that it wants the alternate considered. FDA also encourages a written transliteration of the intended pronunciation.

The review clock

Under FDA’s user-fee commitments for fiscal years 2023 through 2027, the agency aims to review 90 percent of proprietary name submissions within 180 days during development and within 90 days during review of an NDA or BLA. The clock starts only on a complete submission. If a name is found unacceptable, the sponsor can submit a written rebuttal with supporting data or request a meeting within 60 days, and the same review goals apply to the reconsideration or to a new name.

What the misbranding review looks for

Separately from error risk, FDA recommends reviewing a name for anything that overstates efficacy or safety, broadens the indication, implies superiority without substantiation, or is fanciful in a way that suggests unique effectiveness. The guidance gives a plain example: a name that contains or sounds like cure, for a drug that treats the symptoms of a chronic disease, would overstate the clinical benefit. Sound symbolism counts too; FDA notes that the sound of a name can carry meaning on its own.

Prescreening a drug name before anyone falls for it

Many of the attributes FDA typically finds concerning can be caught by the prescreen the guidance describes. Run it on every candidate before trademark searches and research money are spent.

USAN stems in the stem position

The USAN Council assigns stems that signal a pharmacological or chemical class, and FDA recommends keeping them out of proprietary names in the position USAN reserves for them, because a stem can imply a trait the drug does not have and breeds near-identical names. The list of approved stems is the screen. FDA is generally relaxed about the five two-letter stems, which are rarely recognized as stems at all.

Medical abbreviations, numbers and symbols

Letters that already mean something on a prescription, such as abbreviations for a route or a frequency, can turn a name into an instruction. Digits are mistaken for strength or quantity; FDA’s example is a 3 in a name read as three tablets or three days. Symbols such as a plus sign can be read as a 4. Unpronounceable strings like IVS458 are discouraged because prescribers say names out loud. The exceptions are classes with settled conventions, such as numbered oral contraceptive names and insulin mixtures.

Product attributes and modifiers

A root name that bakes in a dosage form or route, FDA’s hypothetical Nametabs or Nameoral, goes stale the moment a new formulation arrives. Modifiers that describe a version are reviewed for whether end users understand them, and FDA suggests checking the established modifiers already in use before coining a new one. For drug-device combinations, the drug name conventionally comes first and the device part follows, either descriptive (Pen, Inhaler) or a coined platform name.

Names used abroad and names built on the sponsor

FDA recommends against a name identical or nearly identical to a foreign product with a different active ingredient, even when the new product will be sold only in the United States. The guidance recounts the case of two different drugs, digoxin and diltiazem, sold under the same name in different countries, and a patient who took the wrong one. Building every name on the company’s own name is discouraged for a similar reason: it manufactures look-alikes.

Claims hiding inside a name

Under 21 CFR 201.10, labeling can be misleading if a fanciful proprietary name implies unique effectiveness or composition for what is in fact a common substance, or if the name can be confused with another drug’s name by its spelling or pronunciation. Inert ingredients should not appear in a name, and a combination product’s name should not suggest only some of its active ingredients.

Trademark clearance and global naming

FDA acceptance and trademark rights are separate tests run by separate agencies; a name has to pass both, in every market where the product will be sold, and the cheapest time to learn that is before the shortlist is presented.

Searching the USPTO record and beyond

USPTO says a likelihood of confusion with an earlier mark is the most common reason it refuses registration, and that marks do not have to be identical to conflict; similar sound, appearance or meaning is enough when the goods are related. The office’s comprehensive clearance guidance lists what a full search covers: the federal Trademark Search system, the Official Gazette, state trademark and business registries, domain registrations, Madrid Monitor, WIPO’s Global Brand Database and the EU’s TMview, plus common-law use found on the web.

The class and the fee

Pharmaceuticals sit in International Class 5, alongside medical and veterinary preparations. USPTO’s trademark fee information puts the base filing fee at $350 per class, with surcharges for applications that lack required information or use free-form descriptions instead of the ID Manual. A name chosen years before launch can be filed on an intent-to-use basis under Section 1(b), which means a further filing and fee once the mark is actually used in commerce.

International filings and the Madrid System

WIPO’s Madrid System lets an owner file one international application and pay one set of fees for protection in up to 133 countries covered by its 117 members, building on a home registration or application. A current detail: according to USPTO, outbound Madrid applications based on US marks moved to WIPO’s Madrid e-Filing on October 1, 2026, which is now the single place to file them.

Europe: EMA’s invented-name review

Pharma marketing in Europe works under different law, and naming is part of it. For medicines assessed centrally, EMA’s invented-name reviewers, known as the NRG and set up by its human medicines committee, check that a proposed name does not convey misleading therapeutic or pharmaceutical connotations, does not mislead about composition and cannot be confused with an existing medicine in print, handwriting or speech. Advertising differs too: Directive 2001/83/EC requires member states to prohibit advertising prescription-only medicines to the general public, and the European Commission proposed in April 2023 to replace that legislation and a political agreement followed in December 2025, so a European brand lives mostly in professional channels.

Nonproprietary names: USAN, INN and biologic suffixes

The established name is not the brand team’s to choose, but it shapes the lockup. In the United States the USAN Council selects it; internationally, WHO assigns International Nonproprietary Names, each a unique name that is global public property. For biological products, FDA’s nonproprietary naming guidance combines a core name with a distinguishing suffix of four lowercase letters that is devoid of meaning, attached with a hyphen, so lockups for biologics must leave room for a longer established name.

Fair balance, promotional labeling and the brand assets they touch

The same regulations that govern a full branded advertisement also govern the logo lockup, the headline and the pictures in it. A brand system that ignores them gets redrawn in review.

The core texts are 21 CFR 202.1 for prescription drug advertisements and 21 CFR 201.10 for labeling, read with FDA’s guidance on product name placement, size and prominence. FDA’s Office of Prescription Drug Promotion reviews advertising and promotional labeling to make sure it is not false or misleading, comments on proposed pieces when sponsors ask, and issues letters when it finds violations. Our part is the naming, identity, packaging design and guidelines, built to these rules; the legal and regulatory judgments stay with the sponsor’s own reviewers.

The established name lockup

When the established name accompanies the proprietary name, it must be printed in letters at least half as large as the letters of the proprietary name, with prominence commensurate with it, taking into account typography, layout and contrast. OPDP reads half as large as actual letter size, not point size, so a condensed or small-x-height typeface can fail a rule that the point sizes appear to pass. For promotional pieces, FDA recommends placing the established name directly to the right of or directly below the proprietary name, with nothing between them; for container labels and cartons, FDA’s carton guidance says there must not be intervening matter between the two names, citing 21 CFR 201.10(a). FDA does not treat the registered or trademark symbol or a controlled-substance symbol as intervening matter.

How often the established name must appear

The rule says the established name accompanies the proprietary name each time it is featured. In print, FDA does not intend to object if it appears at least once per page or spread where the proprietary name is most prominent; on the web, at least once per page where the proprietary name is most prominent, plus once in the running text when the proprietary name is used there. Templates should build that in, so nobody has to remember it on deadline.

Headlines, pictures and graphic matter

Among the presentations 21 CFR 202.1 lists as making an advertisement false, lacking in fair balance or otherwise misleading is one that uses a headline, subheadline, or pictorial or other graphic matter in a misleading way. Imagery is therefore reviewed as a claim: an athlete mid-stride beside a respiratory brand says something about effect, whatever the copy says.

Fair balance inside a branded design

Risk information has to appear with prominence and readability reasonably comparable to the benefit information, judged by typography, layout, contrast, headlines, paragraphing and white space. Design systems that give the safety section its own lighter type style, smaller leading or a tinted box that reduces contrast will be read as de-emphasizing the risk information, which 21 CFR 202.1(e)(7)(viii) treats as a prominence and readability problem. How campaigns carry important safety information in each channel is covered on our pharma advertising agency page.

Reminder pieces, the word new and FDA-approved

A reminder advertisement calls attention to the product name without indications or dosage, and may carry only a defined list of items; apart from price-only reminders, they are not permitted for a product whose labeling has a boxed warning about a serious hazard. OPDP says the regulations do not limit spending on reminder objects such as pens, cups or calendars, but they do limit what the words, graphics and design on them may suggest. OPDP generally accepts new for six months from initial marketing, and FDA-approved once the sponsor holds an approval letter.

First use: Form FDA 2253 and advisory comments

Under 21 CFR 314.81(b)(3)(i), and for biologics 21 CFR 601.12(f), an applicant submits specimens of promotional labeling and advertising at the time of initial dissemination or publication, with a completed Form FDA 2253 and the current prescribing information. FDA does not pre-approve promotional materials except in rare cases, such as products under accelerated approval, which must submit them before use. Sponsors can ask OPDP for advisory comments on launch materials; according to the OPDP FAQs, core launch submissions now pass a five-business-day screening period before the review itself begins.

Brand spots on television and radio

Since the compliance date of November 20, 2024, the major statement in a consumer TV or radio ad has to be presented in a clear, conspicuous and neutral manner: consumer-friendly language, audio at least as understandable as the rest of the ad, matching text on screen in TV ads, legible type and contrast, and no sound or visuals that compete with it. Brand animation, music beds and supers are planned around that window.

Pharma packaging design that survives review

Packaging is where branding and medication safety collide most visibly. FDA’s carton guidance asks for critical information to win the principal display panel, and the brand to stay out of its way.

Pharma packaging design ideas usually start with the shelf: a color, a pattern, a bold mark. FDA’s container label and carton labeling guidance (final, May 2022) starts somewhere else, with the end user who has to find critical safety information on the label. Good pharma box design ideas work inside its recommendations rather than around them.

What belongs on the principal display panel

The principal display panel is the panel most likely to be seen by the end user. FDA recommends it carry the proprietary name, the established or proper name, the dosage form, the strength, the route, any warnings and any controlled-substance schedule, while the Rx only statement, net quantity, manufacturer name and manufacturer logo should not compete with them in size or prominence. Side and back panels take the rest.

Color: differentiation yes, color coding rarely

FDA calls the same or similar colors across a product line a commonly cited factor in look-alike errors, so it recommends using color prudently to draw attention to the name, strength and warnings, and to differentiate products and strengths within a line. It generally recommends against color coding, where a color carries a fixed meaning, outside settings where the code is established. Remember that some users have color vision deficiency and that lighting changes how color reads.

Logos near the proprietary name

FDA recommends not placing a logo immediately before or after the proprietary name on a container or carton, because the logo can look like an extra letter, and not superimposing text over images or logos. Logos, stripes and watermarks may help differentiate products but should not compete with, interrupt or distort critical information.

Corporate trade dress across a product line

A strong house style is a branding asset and a safety risk at the same time. FDA asks sponsors to check whether corporate trade dress makes it hard to tell products, or strengths of the same product, apart, and to build in other means of distinction such as boxing, bolding and type variation.

Pharma logo designs and the identity system

A pharma identity has to work in three registers at once: a corporate mark for the company, product marks that obey the lockup rules, and a patient-facing voice that is calm and readable. Each gets its own design brief.

A pharma industry logo for the company

The corporate mark appears at conferences, on partnering decks and in recruiting, often beside larger names. Pharma design ideas that lean on capsules, molecules and helixes are crowded territory; a mark built on the company’s scientific thesis or its name is easier to own and to clear. Our guide to logo design for medicine covers the visual conventions of the category.

Product marks that are drawn for the lockup

Pharma logo designs for products start from the proprietary name set in a typeface whose actual letter heights are known, with the established name position fixed to the right or below. Custom letterforms are fine, but any symbol joined to the word mark has to be checked against the carton guidance, because a symbol beside the name can read as a letter.

Type, color and accessibility

Brand typefaces are chosen for small sizes as well as large: FDA’s carton guidance warns against thin or condensed fonts that compromise legibility, and against pale color combinations with low contrast. Digital assets meet the same standard on screen. Questions about owning a color are answered in our note on whether a brand can own a color.

Patient-facing voice

Patients read program letters, injection guides and condition pages under stress. Plain words, short sentences and consistent naming of the product and the program across every touchpoint matter more than tone. Healthcare providers get a different, more technical register, carried by the same visual system.

Pharma brand planning: what goes in the plan?

A brand plan connects the evidence, the audiences and the name to a positioning the whole launch team can repeat. It is written before the creative brief, and revised as the label takes shape.

Pharma brand strategy before the name

Pharma brand strategy starts with what the expected label will support, who will prescribe and who will pay, and what the product replaces. The name and identity come after the positioning, not before; a name chosen first can promise something the eventual indication cannot carry, which is what the misbranding review looks for.

From brand plan to launch assets

A pharma brand plan PPT is fine for a steering meeting, but the plan only works when it is translated into tools: a positioning statement, message pillars tied to referenced claims, the identity guidelines, lockup rules and an asset list with owners and review dates. That translation is the part most often skipped.

Research with prescribers, pharmacists and patients

Brand research here is narrower than general pharma marketing research. It tests whether the name is understood, said correctly and never confused, and whether the identity reads as intended. FDA’s guidance describes name simulation studies in which participants meet a name through prescriptions, computer order entry and telephone orders; FDA says it would be useful for sponsors to run more comprehensive ones than its own.

Pharmaceutical branding examples, explained by the rule behind them

The most useful examples are the ones FDA itself publishes, because each shows a naming decision and the reasoning that decides it. These come from FDA’s proprietary name guidance.

A descriptive modifier that works

FDA cites Photrexa Viscous, where the modifier viscous describes the formulation. A modifier earns its place when it describes a real characteristic, end users understand it, and its omission or misreading would not cause harm.

Device names that travel across products

For drug-device combinations, FDA describes descriptive device modifiers such as Pen, Prefilled Syringe or Inhaler, and coined platform modifiers such as SOLOSTAR or Diskus that a sponsor may use across several products, provided the drug portion of each name is distinct and the devices operate in much the same way.

Numbers where a class has a convention

Oral contraceptives often carry a slash, hyphen or number, and FDA mentions names such as Tri-linyah and Junel 1/20; vaccines may carry their valency. Outside such settled conventions, FDA recommends words over numbers and symbols.

A name shared across borders

The guidance’s cautionary example is a single name used for digoxin in one country and diltiazem in another, and the medication error that followed. The lesson for a global brand plan is to search foreign registers and drug compendia, not only the US record.

A name that promises too much

FDA’s example of a name containing or sounding like cure, for a chronic-disease drug that treats symptoms, shows how the sound of a word can overstate benefit. Names suggesting speed, strength or permanence deserve the same scrutiny.

Pharma web design for the corporate and branded sites

The corporate site and the branded product site are separate builds with separate review paths, and the identity system has to serve both without blurring them.

Branded product sites

A product site carries the lockup rules on every page where the proprietary name is most prominent, important safety information within reach and indications stated as labeled. Our healthcare website design page covers the build, accessibility and hosting side.

Corporate and pipeline pages

Pipeline pages describe investigational programs as science, without safety or efficacy claims, which is what 21 CFR 312.7 asks. Clear program names, phases and indications under study, stated as facts, also give search engines and AI assistants something accurate to repeat.

How AI assistants answer questions about pharma brands

ChatGPT, Claude, Perplexity, Gemini, Microsoft Copilot and Google AI Overviews answer from pages they can retrieve and read. A pharma brand is described accurately only if accurate, crawlable pages about it exist.

What people ask

Brand and marketing leads ask assistants for branding agencies with pharma naming experience, for how FDA reviews drug names and for what branding costs. Health care professionals ask what a product is, how it differs from alternatives and how its name is pronounced. Patients ask about conditions and programs. Each question pulls from different pages.

Which sources carry the answer

For product questions, the authoritative sources are the prescribing information, FDA’s own databases, the official product site and medical references, so those are the pages to keep accurate and consistent. For questions about agencies, a page that states plainly what a firm does, for whom and how gives an assistant something specific to repeat; a page of slogans does not.

What a pharma company should publish

Publish the proprietary and established names together, the pronunciation, the labeled indication, a clear pipeline page and consistent company facts, as text rather than images or PDFs. Check that the search crawlers are not blocked in robots.txt: OpenAI’s OAI-SearchBot, PerplexityBot and Anthropic’s Claude-SearchBot each have documented user agents, and Google says there are no additional requirements for AI Overviews or AI Mode beyond normal search practice.

Ads and AI answers

Google shows ads above, below and, for some categories, inside AI Overviews, but its Google Ads help page says it does not currently show ads inside AI Overviews for sensitive verticals, healthcare among them. Prescription drug advertising on Google also requires certification. The full program for AI visibility in this sector is on our AEO for pharma page.

Pharma marketing trends that reach the brand team

Most trend talk is about channels. These are the dated rule and platform changes from the last few years that change brand work itself, each confirmed on the issuing body’s own pages.

• The clear, conspicuous and neutral rule for consumer TV and radio ads took effect on May 20, 2024, with compliance required from November 20, 2024; brand spots are storyboarded around the major statement.
• OPDP added a five-business-day screening period before core launch reviews begin, so launch packages need claim annotations complete on day one.
• Outbound Madrid Protocol filings based on US marks moved to WIPO’s Madrid e-Filing on October 1, 2026.
• Google shows ads in and around AI Overviews in a list of countries that includes the United States, but says it currently keeps them out of AI Overviews for healthcare and other sensitive categories.
• The EU’s pharmaceutical reform, proposed by the European Commission in April 2023, reached a political agreement in December 2025 and the Council’s first-reading position was published on October 1, 2026, with Parliament’s second reading still pending. Directive 2001/83/EC remains the law in force, and European brand plans keep relying on professional channels.
• FDA keeps publishing OPDP’s untitled letters with the promotional material attached, the most practical set of real examples of what reviewers object to.

What does a pharma branding agency do?

It develops the strategy, names and identity, builds the system that keeps them consistent, and prepares assets that pass review the first time. It does not replace the sponsor’s regulatory, medical or legal judgment.

Deliverables by phase

Early: positioning, naming strategy, candidate generation and prescreening. Middle: identity design, lockups, and the candidate material the sponsor’s regulatory team and trademark counsel use in the testing and filings they run. Late: packaging systems, launch asset templates, guidelines and governance.

• Positioning and brand plan aligned with the expected label
• Naming strategy, candidate lists and prescreen reports
• Support for trademark counsel’s knockout and clearance searches
• Pronunciation guides and candidate material for the similarity and simulation testing the sponsor commissions
• Corporate identity: mark, type, color, voice, templates
• Product identity: word mark, lockup rules, measured letter heights
• Packaging and carton design systems with differentiation across strengths
• Launch asset templates with safety information built in
• Brand guidelines and a governance process for agencies and affiliates

Specialist firms and in-house teams

Some sponsors keep strategy in-house and hire specialists for naming, packaging or launch production. Smaller companies usually need one partner who can carry the brand from the corporate identity to the first product. Whether you hire a pharma brand company or build the capability internally, the review process and the documentation are the same.

How much does pharma branding cost?

It is priced by scope, and published US price bands for branding work run from $1,500 for a logo alone to $40,000 to $80,000 and beyond for a complete brand program with research and rollout. Product naming, clearance and packaging systems sit at the upper end.

The bands below are published US price bands for this work (market figures, not a Progression rate card); a quote follows a written scope. They come from our branding pricing guide, which explains each tier in detail.

What pushes a pharma quote up

Name generation and prescreening across several markets, linguistic checks in each language, research support for simulation studies, more than one round of misbranding and medical review, packaging across several strengths, and launch templates for many channels. Trademark counsel’s fees and government filing fees, such as USPTO’s $350 per class, are billed separately.

What keeps it down

A positioning settled before naming starts, a shortlist cut hard at the prescreen, one decision-maker with authority, and review comments consolidated into one round instead of five.

How long does a pharma brand take to build?

A corporate identity project runs about thirteen weeks when decisions are made on time; a product brand runs alongside the late-stage clinical program, because FDA will not look at a name before the end of phase 2 and confirms it only at approval.

1. Positioning and naming strategy while phase 2 data arrive.
2. Candidate generation and prescreening, then trademark knockout searches on the survivors.
3. Similarity scoring and simulation research on a shortlist.
4. Submission of a primary and an alternate name to FDA by the sponsor’s regulatory team once phase 2 is complete.
5. Identity design, lockups and packaging system on the tentatively accepted name.
6. Launch templates, guidelines and the Form 2253 package ready for approval day.

Expect FDA’s own clock to add up to 180 days for a name submitted during development, or 90 days for one filed with the application, and plan the trademark filing on an intent-to-use basis early enough that registration is not the last item.

How to choose a pharma branding agency

Choose on evidence that the agency knows the rules and has a method for them. Portfolios show taste; the questions below show whether a name will survive FDA.

Comparing pharma branding companies

Ask each shortlisted firm the same three questions: how many candidates survive their prescreen, what they would do if FDA rejected the primary name, and how they keep a corporate trade dress from creating look-alike cartons. The answers separate specialists from generalists quickly.

Questions to put to pharmaceutical branding companies

Who on the team has written a name submission package? How do they test pronunciation? What do they need from medical affairs, and when? How do they handle a name that clears in the United States but conflicts in Europe? Will they share the untitled letters they study, and what they learned from them?

Related pharma, healthcare and life sciences pages

Five live pages cover the ground next to this one. Each gets a short paragraph here and is not repeated.

Pharmaceutical marketing

Channels, the medical, legal and regulatory review stages, adverse-event handling and measurement are on our pharma marketing services page, which also covers when to build an in-house team.

Pharma advertising

Paid media for branded and unbranded campaigns, health care professional targeting, platform certification and landing pages with important safety information are on our pharma advertising page.

Healthcare branding

Branding for hospitals, health systems, practices and clinics, where the brand is a place and a service rather than a product, is on our healthcare branding agency page.

Life sciences marketing

Marketing for suppliers, CDMOs, CROs, tools and instrument companies, including research-use-only claims, is on our life sciences marketing agency page.

AEO for pharma

How assistants answer pharma questions, which sources they draw on and how to be cited accurately is on our AEO for pharma page.

Other services that often sit beside a pharma brand program:

• Branding agency services for identity, naming and brand architecture outside regulated products
• Public relations for launch news, financings and executive visibility
• Healthcare public relations for clinical and trade press
• Content marketing for disease education and corporate thought leadership
• Social media marketing for corporate channels and recruiting
• Medical device marketing where a combination product carries a device brand
• Digital healthcare marketing for health technology companies
• B2B branding for CDMOs, CROs and platform companies selling to other companies
• Pharmacy marketing for pharmacy branding ideas that suit a retail or specialty pharmacy
• Executive brand building for founders and scientific leaders
• Healthcare advertising for providers and health services
• The branding pricing guide for every price tier in detail

Working inside the rules

Our role is naming, identity, packaging design and guidelines built to FDA’s naming, labeling and promotion rules and the trademark system. Name-safety testing such as similarity analysis and simulation studies, FDA submissions and the legal and regulatory decisions are commissioned and owned by the sponsor’s regulatory team and counsel.

This page describes the rules and guidance as published on October 13, 2026. Guidance documents are FDA’s current thinking and are not binding unless they cite a requirement; regulations and statutes are. Nothing here is legal or regulatory advice.

Frequently asked questions